Page last updated: 2024-12-09

1-ethyl-3-[[[(phenylmethyl)amino]-sulfanylidenemethyl]amino]thiourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-ethyl-3-[[[(phenylmethyl)amino]-sulfanylidenemethyl]amino]thiourea is a **complex organic compound** with a rather complicated structure. It's important to break down its name and structure to understand its potential significance:

**Structure:**

* **Thiourea:** The core of the molecule is thiourea, which contains a sulfur atom double-bonded to a carbon atom, connected to two nitrogen atoms.
* **Ethyl group:** Attached to one of the nitrogen atoms is an ethyl group (-CH2CH3).
* **Phenylmethyl group:** The other nitrogen is linked to a more complex structure: a phenylmethyl group (-CH2-C6H5), which is a benzyl group.
* **Sulfanylidenemethyl group:** This group (-CH=S-) links the benzyl group to the thiourea core.

**Importance in Research:**

While the specific compound you mentioned may not be well-documented, similar thiourea derivatives are often explored in research for various reasons:

* **Biological Activity:** Thioureas are known for their diverse biological activities, including potential as:
* **Antimicrobial agents:** They can inhibit the growth of bacteria and fungi.
* **Anti-cancer agents:** Some thiourea derivatives can inhibit tumor cell growth.
* **Anti-inflammatory agents:** They may reduce inflammation in the body.
* **Material Science:** Certain thioureas are employed in the synthesis of polymers and other materials. Their ability to form strong bonds makes them useful for various applications.
* **Analytical Chemistry:** Thioureas are sometimes used as reagents in analytical chemistry, due to their ability to form complexes with metal ions.

**To understand the specific importance of 1-ethyl-3-[[[(phenylmethyl)amino]-sulfanylidenemethyl]amino]thiourea, further information is needed.**

**Possible Research Avenues:**

* **Synthesis and Characterization:** Determining the most effective methods for synthesizing the compound and characterizing its properties (structure, melting point, solubility, etc.).
* **Biological Activity:** Evaluating the compound's effects on various biological systems (bacterial growth, cancer cell lines, inflammatory processes).
* **Material Science Applications:** Investigating potential uses in materials science, such as polymers, coatings, or other materials.

**Finding More Information:**

To learn more about this specific compound, you would need to search for research publications that mention its name or chemical structure. You can use databases like PubChem, SciFinder, or Google Scholar for this purpose.

Cross-References

ID SourceID
PubMed CID1825238
CHEMBL ID1408451
CHEBI ID107326

Synonyms (23)

Synonym
HMS2583D21
MLS-0232971.0002 ,
MLS-0232971.0001
n~1~-benzyl-n~2~-ethyl-1,2-hydrazinedicarbothioamide
MLS000705903
smr000225838
n-benzyl-n'-ethylhydrazine-1,2-dicarbothioamide
STK079642
CHEBI:107326
AKOS000352261
1-benzyl-3-(ethylcarbamothioylamino)thiourea
bdbm43805
cid_1825238
1-ethyl-3-[[[(phenylmethyl)amino]-sulfanylidenemethyl]amino]thiourea
1-benzyl-3-(ethylthiocarbamoylamino)thiourea
1-ethyl-3-[(phenylmethyl)carbamothioylamino]thiourea
HNVKQXJBINMTGG-UHFFFAOYSA-N
benzene, 1-[[[[2-[(ethylamino)carbonothioyl]hydrazino]carbonothioyl]amino]methyl]-
CHEMBL1408451
Q27185555
1-[(benzylcarbamothioyl)amino]-3-ethylthiourea
SR-01000534920-1
sr-01000534920
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00320.003245.467312,589.2998AID2517
Chain A, Beta-lactamaseEscherichia coli K-12Potency89.12510.044717.8581100.0000AID485294
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency1.25890.631035.7641100.0000AID504339
phosphopantetheinyl transferaseBacillus subtilisPotency56.23410.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686978; AID686979
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency0.63100.707912.194339.8107AID720542
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency10.00000.035520.977089.1251AID504332
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency3.52100.036619.637650.1187AID2100
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency35.48131.000012.232631.6228AID1452
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency28.18380.001815.663839.8107AID894
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency21.28040.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency32.64270.004611.374133.4983AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency1.25890.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
alkaline phosphatase, germ cell type preproproteinHomo sapiens (human)IC50 (µMol)100.00000.110011.386267.2000AID1512
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
alkaline phosphatase, tissue-nonspecific isozyme isoform 1 preproproteinHomo sapiens (human)EC50 (µMol)15.59330.227025.090486.8000AID1001; AID1450; AID1659
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]